ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

[1]  M. Breakspear,et al.  Harmonised collection of data in youth mental health: Towards large datasets , 2019, The Australian and New Zealand journal of psychiatry.

[2]  J. Vohs,et al.  Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders , 2018, Schizophrenia Research.

[3]  A. Egerton,et al.  Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia , 2018, Psychopharmacology.

[4]  D. Wechsler.  Wechsler Abbreviated Scale of Intelligence--Second Edition , 2018 .

[5]  N. Baker,et al.  The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. , 2018, Drug and alcohol dependence.

[6]  A. Egerton,et al.  O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA , 2018, Schizophrenia bulletin.

[7]  M. Berk,et al.  Mitochondrial Agents for Bipolar Disorder , 2018, The international journal of neuropsychopharmacology.

[8]  Heng Du,et al.  Antioxidant Treatment in Male Mice Prevents Mitochondrial and Synaptic Changes in an NMDA Receptor Dysfunction Model of Schizophrenia , 2017, eNeuro.

[9]  A. Gadelha,et al.  Oxidative and nitrosative stress biomarkers in chronic schizophrenia , 2017, Psychiatry Research.

[10]  M. Yücel,et al.  Quetiapine v. lithium in the maintenance phase following a first episode of mania: Randomised controlled trial , 2017, British Journal of Psychiatry.

[11]  Celso Arango,et al.  Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis , 2017, The international journal of neuropsychopharmacology.

[12]  D. Volk.  Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia , 2017, Neurobiology of Disease.

[13]  Rolf Gruetter,et al.  N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis , 2017, Schizophrenia bulletin.

[14]  R. Kahn,et al.  Immune involvement in the pathogenesis of schizophrenia: a meta-analysis on postmortem brain studies , 2017, Translational Psychiatry.

[15]  Alan A. Wilson,et al.  Imaging Microglial Activation in Untreated First-Episode Psychosis: A PET Study With [18F]FEPPA. , 2017, American Journal of Psychiatry.

[16]  D. Goldsmith,et al.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.

[17]  M. Berk,et al.  Cognitive effects of adjunctive N-acetyl cysteine in psychosis , 2016, Psychological Medicine.

[18]  Paul G. Unschuld,et al.  Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A 1H MRS Study at 7Tesla , 2016, Schizophrenia Research.

[19]  S. Ivanova,et al.  Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy , 2015, Bulletin of Experimental Biology and Medicine.

[20]  Alessandra Bertoldo,et al.  Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study. , 2015, The American journal of psychiatry.

[21]  Deepmala,et al.  Neuroscience and Biobehavioral Reviews Clinical Trials of N-acetylcysteine in Psychiatry and Neurology: a Systematic Review , 2022 .

[22]  H. Nasrallah,et al.  Managing First-Episode Psychosis: An Early Stage of Schizophrenia with Distinct Treatment Needs: Minimize Duration of Untreated Psychosis; Aim for Remission , 2015 .

[23]  R Gruetter,et al.  Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients , 2014, Molecular Psychiatry.

[24]  R. Kahn,et al.  The neurobiology and treatment of first-episode schizophrenia , 2014, Molecular Psychiatry.

[25]  M. Berk,et al.  The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. , 2014, The Journal of clinical psychiatry.

[26]  J. Leza,et al.  Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study , 2014, Schizophrenia Research.

[27]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[28]  P. Mortensen,et al.  The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis , 2014, Biological Psychiatry.

[29]  J. Richardson,et al.  Validity and Reliability of the Assessment of Quality of Life (AQoL)-8D Multi-Attribute Utility Instrument , 2013, The Patient - Patient-Centered Outcomes Research.

[30]  S. Akhondzadeh,et al.  N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study , 2013, Clinical neuropharmacology.

[31]  Peter Buckley,et al.  Meta-Analysis of Oxidative Stress in Schizophrenia , 2013, Biological Psychiatry.

[32]  Michael Berk,et al.  The chemistry and biological activities of N-acetylcysteine. , 2013, Biochimica et biophysica acta.

[33]  P. Buckley,et al.  Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects , 2013, Biological Psychiatry.

[34]  M. Berk,et al.  Putative neuroprotective agents in neuropsychiatric disorders , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  P. Das,et al.  Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo , 2013, The Australian and New Zealand journal of psychiatry.

[36]  D. Rennie,et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.

[37]  M. Cairns,et al.  Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia , 2013, Molecular Psychiatry.

[38]  K. Brady,et al.  A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. , 2012, The American journal of psychiatry.

[39]  M. Knyazeva,et al.  Glutathione Precursor N-Acetyl-Cysteine Modulates EEG Synchronization in Schizophrenia Patients: A Double-Blind, Randomized, Placebo-Controlled Trial , 2012, PloS one.

[40]  A. Chanen,et al.  Treating co‐occurring first‐episode psychosis and borderline personality: a pilot randomized controlled trial , 2012, Early intervention in psychiatry.

[41]  P. Mortensen,et al.  Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. , 2011, The American journal of psychiatry.

[42]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[43]  V. Nimgaonkar,et al.  Genetic association studies of antioxidant pathway genes and schizophrenia. , 2011, Antioxidants & redox signaling.

[44]  Alan S. Brown,et al.  Maternal infection and schizophrenia: implications for prevention. , 2011, Schizophrenia bulletin.

[45]  M. Lambert,et al.  Prevalence, Predictors, and Consequences of Long-Term Refusal of Antipsychotic Treatment in First-Episode Psychosis , 2010, Journal of clinical psychopharmacology.

[46]  D. Polit,et al.  Intention-to-treat in randomized controlled trials: recommendations for a total trial strategy. , 2010, Research in nursing & health.

[47]  Alan S. Brown,et al.  Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. , 2010, The American journal of psychiatry.

[48]  河盛 隆造,et al.  MRI(magnetic resonance imaging),MRS(magnetic resonance spectroscopy)の複合的利用による新規骨格筋機能マーカーの探求(平成19年度学長特別共同プロジェクト研究報告書) , 2008 .

[49]  S. Wood,et al.  Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. , 2008, The Journal of clinical psychiatry.

[50]  R. Boellaard,et al.  Microglia Activation in Recent-Onset Schizophrenia: A Quantitative (R)-[11C]PK11195 Positron Emission Tomography Study , 2008, Biological Psychiatry.

[51]  K. Fletcher,et al.  Handbook of Psychiatric Measures, 2nd Edition , 2008 .

[52]  M. Berk,et al.  N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder—A Double-Blind Randomized Placebo-Controlled Trial , 2008, Biological Psychiatry.

[53]  M. Cuénod,et al.  N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial , 2008, Biological Psychiatry.

[54]  Reto Meuli,et al.  Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients , 2008, Neuropsychopharmacology.

[55]  M. Lambert,et al.  Treated incidence of first‐episode psychosis in the catchment area of EPPIC between 1997 and 2000 , 2006, Acta psychiatrica Scandinavica.

[56]  J. Lieberman,et al.  Psychosocial treatment for first-episode psychosis: a research update. , 2005, The American journal of psychiatry.

[57]  A. Malla,et al.  First-Episode Psychosis, Early Intervention, and Outcome: What Have We Learned? , 2005, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[58]  Jim van Os,et al.  Size of burden of schizophrenia and psychotic disorders , 2005, European Neuropsychopharmacology.

[59]  R. Yolken,et al.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress , 2004, Molecular Psychiatry.

[60]  M. Rubio‐Stipec,et al.  The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. , 2002, Addiction.

[61]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.

[62]  D. Moher,et al.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials , 2001, The Lancet.

[63]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[64]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[65]  Michael B. First,et al.  Handbook of Psychiatric Measures , 2000 .

[66]  A. Sergejew,et al.  Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses , 2000, Schizophrenia Research.

[67]  L. Garey,et al.  Increase in HLA‐DR Immunoreactive Microglia in Frontal and Temporal Cortex of Chronic Schizophrenics , 2000, Journal of neuropathology and experimental neurology.

[68]  D. Sheehan,et al.  The measurement of disability. , 1996 .

[69]  H. Goldman,et al.  Revising axis V for DSM-IV: a review of measures of social functioning. , 1992, The American journal of psychiatry.

[70]  B. Goldman.  Dr. Goldman replies. , 1984 .

[71]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[72]  D. Wechsler.  Wechsler Adult Intelligence Scale , 2021, Encyclopedia of Evolutionary Psychological Science.

[73]  S. Rosenbaum,et al.  The Simple Physical Activity Questionnaire. , 2016, The lancet. Psychiatry.

[74]  C. Ross,et al.  Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A 1 H MRS Study at 7 Tesla , 2016 .

[75]  Alan A. Wilson,et al.  Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. , 2015, Schizophrenia bulletin.

[76]  P. McGorry,et al.  Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health , 2015, Social Psychiatry and Psychiatric Epidemiology.

[77]  David Moher,et al.  SPIRIT 2013 Statement: defining standard protocol items for clinical trials. , 2015, Revista panamericana de salud publica = Pan American journal of public health.

[78]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[79]  T. Insel.  Rethinking schizophrenia , 2010, Nature.

[80]  J. Lani.  Rey Auditory Verbal Learning Test (RAVLT) , 2010 .

[81]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[82]  J. Bolton,et al.  Assessing the clinical significance of change scores recorded on subjective outcome measures. , 2004, Journal of manipulative and physiological therapeutics.

[83]  R. Yolken,et al.  Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress , 2004, Molecular Psychiatry.

[84]  J. J. Ryan,et al.  Wechsler Adult Intelligence Scale-III , 2001 .

[85]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.